Key takeaways
- • Trial: SELECT (NCT03574597) — Phase 3, 17,604 participants over 208 weeks.
- • Drug studied: Wegovy (Semaglutide) — FDA-approved branded product.
- • Primary endpoint: Time to first major adverse cardiovascular event (CV death, nonfatal MI, nonfatal stroke) in adults with preexisting CV disease and overweight/obesity (without diabetes)
- • Key result: 20% relative risk reduction in MACE on semaglutide 2.4mg vs placebo (HR 0.80, 95% CI 0.72-0.90)
- • Published: New England Journal of Medicine, 2023.
Study design
SELECT was a phase 3 randomized controlled trial enrolling 17,604 participants over 208 weeks. The trial studied Wegovy (Semaglutide) for cardiovascular outcomes and was published in New England Journal of Medicine in 2023.
Primary endpoint
Time to first major adverse cardiovascular event (CV death, nonfatal MI, nonfatal stroke) in adults with preexisting CV disease and overweight/obesity (without diabetes)
Key results
| Measure | Value |
|---|---|
| Headline result | 20% relative risk reduction in MACE on semaglutide 2.4mg vs placebo (HR 0.80, 95% CI 0.72-0.90) |
| Participants | 17,604 |
| Duration | 208 weeks |
| Phase | Phase 3 |
Citation
SELECT. Published in New England Journal of Medicine, 2023.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Wegovy drug page — pricing, FDA status, side effects, alternatives
- All semaglutide trials
- GLP-1 clinical trials database
Other Wegovy trials
- STEP-1 — Mean weight loss 14
- STEP-2 — Mean weight loss 9
- STEP-3 — Mean weight loss 16
- STEP-4 — Participants continuing semaglutide lost an additional 7
- STEP-5 — Mean weight loss 15
Other Semaglutide trials
- SUSTAIN-1 (Ozempic) — HbA1c reduction 1
- SUSTAIN-6 (Ozempic) — 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0
Important: This trial was conducted on the FDA-approved branded product Wegovy. Compounded versions of Semaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.